References
- Bergman AJ, Cote J, Yi B, et al. (2007). Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862–4
- Boulton DW, Li L, Frevert EU, et al. (2011). Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 50:253–65
- Buteau J, Foisy S, Rhodes CJ, et al. (2001). Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50:2237–43
- Deacon CF, Nauck MA, Toft-Nielsen M, et al. (1995). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–31
- Edwards CM, Todd JF, Mahmoudi M, et al. (1999). Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48:86–93
- Eto T, Inoue S, Kadowaki T. (2012). Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 14:1040–6
- Flint A, Raben A, Astrup A, Holst JJ. (1998). Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515–20
- Guo Z, Raeissi S, White RB, Stevens JC. (1997). Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 25:390–3
- Halabi A, Maatouk H, Siegler KE, et al. (2013). Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharmacol Drug Develop. [Epub ahead of print]. DOI:10.1002/cpdd.29. Published online: 14 May 2013
- Holst JJ, Deacon CF. (1998). Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663–70
- Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- Krause RJ, Lash LH, Elfarra AA. (2003). Human kidney flavin-containing monooxygenases and their potential roles in cysteine S-conjugate metabolism and nephrotoxicity. J Pharmacol Exp Ther 304:185–91
- Kreymann B, Williams G, Ghatei MA, Bloom SR. (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–4
- Miyaoka T, Isono Y, Setani K, et al. (2007). Bioanalysis works in the IAA AMS facility: comparison of AMS analytical method with LSC method in human mass balance study. Nuclear Inst Methods Phys Res 259:779–85
- Overby LH, Carver GC, Philpot RM. (1997). Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29–45
- Scheen AJ. (2010). Dipeptidylpeptitase-4 inhibitors (gliptins). Focus on drug–drug interactions. Clin Pharmacokinet 49:573–88
- Vincent SH, Reed JR, Bergman AJ, et al. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533–8
- Wettergren A, Schjoldager B, Mortensen PE, et al. (1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665–73
- Xu G, Stoffers DA, Habener JF, Bonner-Weir S. (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–6
- Zhou D, Zhang M, Ye X, et al. (2011). In vitro metabolism of α7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite. Xenobiotica 41:232–42